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Figure 2. Total HepG2 lipid content after BDE 
treatment. 
Evaluation of BDE-47 and -99 lipid modulating effects in HepG2 human 
carcinoma cells 
Eileen Holovac, Prajakta Shimpi, Angela Slitt 
University of Rhode Island College of Pharmacy 
Background 
Non-alcoholic fatty liver disease (NAFLD) is becoming a significantly more common 
problem in today’s society, affecting up to 25% of people in the United States as reported by 
the American Liver Foundation. According to the American Association of the Study of Liver 
Diseases, NAFLD is the buildup of fat in the liver that is not caused by secondary factors such 
as alcohol consumption, hereditary disorders, or the use of steatogenic medication such as 
amioderone. A liver is considered fatty when 5-10% of the liver’s weight is fat. The 
progression of NAFLD can lead to cirrhosis, liver cancer, or liver failure. Risk factors for 
NAFLD include obesity, type II diabetes mellitus, hypertriglyceridemia, 
hypercholesterolemia, age, gender, and ethnicity. In addition, there are examples of toxicant-
induced liver disease in occupationally exposed workers, suggesting that the environment may 
also be a risk factor for the development of NAFLD. This study aims to determine whether 
direct exposure to environmental compounds cause fatty liver using cultured liver carcinoma 
cells.  
Introduction 
BDE-47 (2,2′,4,4′-tetra-bromodiphenyl ether) is a brominated flame retardant used in a wide 
variety of consumer products such as polyurethane foam, which is used in furniture and car 
upholstery, packaging and electronic equipment . BDE-47 is released into the environment by 
manufacturers and by the products themselves and can be ingested or inhaled and then stored 
in the liver as lipids. The pentaBDE congener that is usually predominant in environmental 
media is BDE-99 (2,2′,4,4′,5-penta-bromodiphenyl ether). BDE-99 is a brominated flame 
retardant chemical and is released into the environment. PentaBDEs are thought to be 
distributed through the human body and found in adipose tissues, blood, liver, and maternal 
milk. My hypothesis is that BDE-47 and BDE-99 will increase the total lipid content in 
cultured HepG2 liver carcinoma cells. 
 
 
BDE-47 (2,2′,4,4′-tetra-
bromodiphenyl ether) 
 
• Abundance: 38-42% 
BDE-99 (2,2′,4,4′,5-penta-
bromodiphenyl ether) 
 
• Abundance: 45-49% 
Pentabromodiphenyl Ethers 
Hepatic Lipid Homeostasis 
Hepatic Steatosis Progression 
Conclusion 
BDE exposure may increase the risk of non-alcoholic fatty liver 
disease. BDE 47 showed the most prominent effects on HepG2 cells 
leading to hepatic steatosis.  
Future Plan 
Future research will be conducted on the mechanism of BDE-induced 
non-alcoholic fatty liver disease. We will be researching other genes 
that may be involved in BDE-induced non-alcoholic fatty liver disease 
through the use of Real-time PCR.  We will also be using different 
time frames for BDE treatment. 
 
Data/Results 
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Methods and Materials 
 HepG2 Cells: 
HepG2 cells  are a human 
liver carcinoma cell line 
derived from a 15-year old 
Caucasian male . Hepg2 cells 
are  a good in vitro model 
system for this study because 
they have morphological and 
functional differentiation 
which accurately represents 
human liver cells. 
 
HepG2 Cells 
Harvest cells 
in PBS 
Grow HepG2 cells in 
T-75 flask (DMEM + 
10% FBS + 1%P/S + 
1% NEAA 
Plate cells in 6-
well plate 
Treat cells with 
different compounds 
80%  
Confluent 
24 hours 
 later 
Harvest 
cells in 
PBS 
200 μl 
centrifuge 
at 5000 
rpm at 
4°C 
Cell pellet was 
suspended in 
RIPA buffer to 
isolate total 
protein 
Centrifuge at 
12000 rpm at 4°C 
and collected 
supernatant which 
is total protein 
Chlorofom
-methanol 
extraction 
Chlorofrom-
methanol layer put 
in glass tube and 
dried out by using 
speedvac for 2.5 
hrs at 45 °C 
Lipid pellet 
suspended in 
1 % triton 
ethanol 
TG were quantified 
by UV 
spectrophotometry 
using Pointe 
scientific triglyceride 
kit by at 540nm. 
Protein 
concentration 
determined by 
Lowry's Assay used 
to normalized 
triglyceride  level. 
Procedure of HepG2 cells grow and passaging, seeding plates: Triglyceride quantification: 
 After 24hrs of BDE treatment , cells were fixed with 10% formalin and stained with 
Oil Red O working solution made in isopropranalol. After washing with water, cell 
plates were observed under a phase contrast microscope to aquire images.  For ORO 
quantification ORO was extracted by using 100% isopropanol and measured 
absorbance by UV spectrophotometry at 500nm.  
Oil Red O (ORO):  
After treatment with BDEs, RNA was extracted from the cells using Trizol Reagent. 
mRNA was reverse transcribed to cDNA and the relative abundance of transcripts 
related to lipid transport and synthesis was measured via qPCR. The PCR primers 
were optimized for measurement of multiple genes involved in lipid homeostasis. 
 
Gene Expression: 
DMSO BDE 47 0.1μM BDE 47- 1μM 
BDE 47- 5μM BDE 47- 25μM 
BDE 99- 5μM BDE 99- 20μM 
Oleic Acid 
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Oleic acid co-treatment increased lipid content.  0.1 
mM BDE 47 increased lipid content in HepG2 cells. 
In agreement with total lipids, TG levels also 
increased with 5mM BDE 47 treatment.  Oleic acid 
co-treatment increased TG content in 1 and 25mM 
BDE 47 and 1mM BDE 99. 
Figure 1:  A. Total lipid accumulation in HepG2 cells 
was measured after treatment of vehicle or different 
doses of BDE-47 and 99 along with oleic acid. After 
24hrs of treatment total lipids were extracted and dried 
in a glass tube using a speedvac. The weight of the 
lipid pellet was noted. Total lipid content is 
represented as normalized to control group and one-
way ANOVA followed by Dunnett’s test were applied 
to compare treatment exposure versus control group. 
 
B. Triglycerides from the solubilized lipid pellet were 
quantified by calorimetric methods. The triglyceride 
content is represented as normalized to control group 
and one way ANOVA followed by Dunnett’s test were 
applied to compare BDEs exposed versus control 
group. 
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Figure 2: A. Oil Red  O staining to 
observe lipid deposition. Images 
were obtained by brightfield 
microscope (200X). 
B. Oil Red O staining in images 
were quantified by using Image J 
software and data was plotted as 
percentage fold change as compared 
to vehicle. 
Total Lipids 
Triglycerides 
Figure 3: Messenger RNA expression of 
sterol regulatory element binding protein 1c 
(Srebp1c) and fatty acid synthase (Fas) 
HePG2 cells. Data is represented as 
normalized to GAPDH (houekeeping gene). 
Differences between groups were determined 
by one-way ANOVA. Asterisk (*)  represents 
significant difference in BDEs treatment as 
compared to vehicle ((P≤ 0.05).  
 
None of the BDE exposure levels were able 
to induce the lipogenic target gene 
expression in HepG2 cells.  Unexpectedly, 
1mM BDE 47 decreased SREBP-1C mRNA 
expression.   
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SREBP-1C 
FAS 
As compared to DMSO, BDE 
treated cells had higher Oil Red O 
staining. Quantification of the  
images also demonstrated a 
significant increase in lipids in all 
BDE treated groups. 
 
BDEs Pre-dispose to 
hepatic steatosis 
Lipids/Triglycerides 
HepG2 Cell 
Data/Results 
Normal Liver 
Non-alcoholic fatty 
liver disease 
Nonalcoholic 
steatohepatitis 
Cirrhosis/ Liver 
failure 
Adipose 
Tissue 
Acetyl Co-A  
Malonyl CoA 
Acc-1 
Fas 
FA TG 
Gpat 
Ppar-γ 
De-novo lipogenesis 
Srebp1 
Dietary 
fat 
Compounds Final concentration  Working stock 
(1000X)  
Sstock solution /ml of 
media  
DMSO 0.1% 100% 1ul 
Oleic Acid 750 um 3 mM 250 ul 
BDE 47 0.1um (100nm) 100 um 1ul  
  1 um  1 mM 1ul 
  5 um 5 mM 1ul 
  25 um 25mM 1ul 
BDE 99 0.1um (100nm) 100 um 1ul  
  1 um  1 mM 1ul 
  5 um 5 mM 1ul 
  20 um 20mM 1ul 
